#BEGIN_DRUGCARD DB00445

# AHFS_Codes:
10:00.00

# ATC_Codes:
L01DB03

# Absorption:
100%

# Biotransformation:
Extensively and rapidly metabolized in the liver. Epirubicin is also metabolized by other organs and cells, including red blood cells. The four main metabolic routes are: (1) reduction of the C-13 keto-group with the formation of the 13(S)-dihydro derivative, epirubicinol; (2) conjugation of both the unchanged drug and epirubicinol with glucuronic acid; (3) loss of the amino sugar moiety through a hydrolytic process with the formation of the doxorubicin and doxorubicinol aglycones; and (4) loss of the amino sugar moiety through a redox process with the formation of the 7-deoxy-doxorubicin aglycone and 7-deoxy-doxorubicinol aglycone. Epirubicinol exhibits in vitro cytoxic activity (~10% that of epirubicin), but it is unlikely to reach sufficient concentrations in vivo to produce cytotoxic effects.

# Brand_Mixtures:
Not Available

# Brand_Names:
4'-Epiadriamycin
4'-Epidoxorubicin
Ellence
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
IMI 28
Pharmorubicin Pfs
Pidorubicina [INN-Spanish]
Pidorubicine [INN-French]
Pidorubicinum [INN-Latin]
Ridorubicin

# CAS_Registry_Number:
56420-45-2

# ChEBI_ID:
47898

# Chemical_Formula:
C27H29NO11

# Chemical_IUPAC_Name:
(8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2069512

# Description:
An anthracycline which is the 4&#39;-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. [PubChem]

# Dosage_Forms:
Solution	Intravenous
Solution	Intravenous

# Drug_Category:
Antibiotics, Antineoplastic
Antineoplastic Agents

# Drug_Interactions:
Cimetidine	Cimetidine can increase epirubicin levels
Trastuzumab	Trastuzumab may increase the cardiotoxicity of Epirubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.5

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
0.093 mg/ml

# Food_Interactions:
Liberal fluid intake to increase urine output and help the excretion of uric acid.

# GenBank_ID:
Not Available

# Generic_Name:
Epirubicin

# HET_ID:
Not Available

# Half_Life:
Half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively

# InChI_Identifier:
InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1

# InChI_Key:
InChIKey=AOJJSUZBOXZQNB-VTZDEGQISA-N

# Indication:
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

# KEGG_Compound_ID:
C11230

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
445

# Mechanism_Of_Action:
Epirubicin has antimitotic and cytotoxic activity. It inhibits nucleic acid (DNA and RNA) and protein synthesis through a number of proposed mechanisms of action: Epirubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. It also interferes with DNA replication and transcription by inhibiting DNA helicase activity.

# Melting_Point:
344.53 Â°C

# Molecular_Weight_Avg:
543.5193

# Molecular_Weight_Mono:
543.174060775

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449476

# Pharmacology:
Epirubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Epirubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Epirubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.

# Predicted_LogP_Hydrophobicity:
1.41

# Predicted_LogS:
-2.7

# Predicted_Water_Solubility:
1.18e+00 g/l

# Primary_Accession_No:
DB00445

# Protein_Binding:
77%

# PubChem_Compound_ID:
41867

# PubChem_Substance_ID:
46507282

# RxList_Link:
http://www.rxlist.com/cgi/generic2/epirub.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00361

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
bone marrow aplasia, grade 4 mucositis, and gastrointestinal bleeding

# Update_Date:
2013-02-08 16:19:21 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Epirubicin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
PLA2G4A

# Phase_1_Metabolizing_Enzyme_1_ID:
723

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytosolic phospholipase A2

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytosolic phospholipase A2
MSFIDPYQHIIVEHQYSHKFTVVVLRATKVTKGAFGDMLDTPDPYVELFISTTPDSRKRT
RHFNNDINPVWNETFEFILDPNQENVLEITLMDANYVMDETLGTATFTVSSMKVGEKKEV
PFIFNQVTEMVLEMSLEVCSCPDLRFSMALCDQEKTFRQQRKEHIRESMKKLLGPKNSEG
LHSARDVPVVAILGSGGGFRAMVGFSGVMKALYESGILDCATYVAGLSGSTWYMSTLYSH
PDFPEKGPEEINEELMKNVSHNPLLLLTPQKVKRYVESLWKKKSSGQPVTFTDIFGMLIG
ETLIHNRMNTTLSSLKEKVNTAQCPLPLFTCLHVKPDVSELMFADWVEFSPYEIGMAKYG
TFMAPDLFGSKFFMGTVVKKYEENPLHFLMGVWGSAFSILFNRVLGVSGSQSRGSTMEEE
LENITTKHIVSNDSSDSDDESHEPKGTENEDAGSDYQSDNQASWIHRMIMALVSDSALFN
TREGRAGKVHNFMLGLNLNTSYPLSPLSDFATQDSFDDDELDAAVADPDEFERIYEPLDV
KSKKIHVVDSGLTFNLPYPLILRPQRGVDLIISFDFSARPSDSSPPFKELLLAEKWAKMN
KLPFPKIDPYVFDREGLKECYVFKPKNPDMEKDCPTIIHFVLANINFRKYKAPGVPRETE
EEKEIADFDIFDDPESPFSTFNFQYPNQAFKRLHDLMHFNTLNNIDVIKEAMVESIEYRR
QNPSRCSVSLSNVEARRFFNKEFLSKPKA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P47712

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
UGT2B7

# Phase_1_Metabolizing_Enzyme_2_ID:
6178

# Phase_1_Metabolizing_Enzyme_2_Name:
UDP-glucuronosyltransferase 2B7

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>UDP-glucuronosyltransferase 2B7
MSVKWTSVILLIQLSFCFSSGNCGKVLVWAAEYSHWMNIKTILDELIQRGHEVTVLASSA
SILFDPNNSSALKIEIYPTSLTKTELENFIMQQIKRWSDLPKDTFWLYFSQVQEIMSIFG
DITRKFCKDVVSNKKFMKKVQESRFDVIFADAIFPCSELLAELFNIPFVYSLSFSPGYTF
EKHSGGFIFPPSYVPVVMSELTDQMTFMERVKNMIYVLYFDFWFEIFDMKKWDQFYSEVL
GRPTTLSETMGKADVWLIRNSWNFQFPHPLLPNVDFVGGLHCKPAKPLPKEMEDFVQSSG
ENGVVVFSLGSMVSNMTEERANVIASALAQIPQKVLWRFDGNKPDTLGLNTRLYKWIPQN
DLLGHPKTRAFITHGGANGIYEAIYHGIPMVGIPLFADQPDNIAHMKARGAAVRVDFNTM
SSTDLLNALKRVINDPSYKENVMKLSRIQHDQPVKPLDRAVFWIEFVMRHKGAKHLRVAA
HDLTWFQYHSLDVIGFLLVCVATVIFIVTKCCLFCFWKFARKAKKGKND

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P16662

# Drug_Target_1_Cellular_Location:
Nucleus

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CHD1

# Drug_Target_1_GenBank_ID_Gene:
AF006513

# Drug_Target_1_GenBank_ID_Protein:
2645429

# Drug_Target_1_GeneCard_ID:
CHD1

# Drug_Target_1_Gene_Name:
CHD1

# Drug_Target_1_Gene_Sequence:
>5130 bp
ATGAATGGACACAGTGATGAAGAAAGTGTTAGAAACAGTAGTGGAGAATCAAGCCAGTCG
GATGATGATTCTGGGTCAGCTTCAGGCTCTGGATCTGGTTCGAGTTCTGGAAGCAGTAGT
GATGGAAGCAGTAGCCAGTCAGGTAGCAGTGACTCTGACTCCGGATCTGAATCAGGCAGT
CAGTCAGAGTCTGAGTCAGACACTTCCCGAGAAAACAAAGTTCAAGCAAAACCACCGAAA
GTTGATGGAGCTGAGTTTTGGAAATCTAGTCCTAGTATTCTGGCCGTTCAGAGATCTGCA
ATCCTCAAGAAGCAGCAACAGCAGCAGCAGCAACAACAACATCAAGCCTCATCTAATAGC
GGATCAGAAGAGGATTCCTCTAGCAGTGAAGATTCCGATGACTCATCAAGTGAGGTCAAA
AGGAAAAAGCATAAAGATGAAGATTGGCAAATGTCTGGGTCAGGATCTCCATCTCAGTCT
GGTTCAGATTCAGAATCTGAAGAAGAGAGAGAGAAAAGCAGTTGTGATGAAACAGAATCT
GATTATGAGCCAAAAAACAAAGTCAAAAGCAGAAAACCTCAAAATAGATCTAAGTCAAAA
AATGGAAAGAAGATTCTTGGACAAAAAAAGAGACAGATTGATTCATCTGAGGAGGATGAT
GATGAAGAAGATTATGATAATGATAAAAGAAGTTCTCGTCGCCAAGCAACTGTTAATGTT
AGCTATAAGGAGGATGAAGAAATGAAAACAGATTCTGATGACCTACTGGAAGTCTGTGGA
GAGGATGTTCCTCAACCTGAGGAAGAGGAATTTGAAACCATAGAAAGATTTATGGATTGT
CGGATTGGGAGAAAAGGAGCTACTGGTGCTACTACAACCATCTATGCAGTTGAAGCAGAT
GGTGACCCAAATGCAGGCTTTGAAAAAAACAAAGAACCAGGAGAGATTCAGTATTTAATT
AAATGGAAAGGATGGTCCCATATCCACAACACTTGGGAGACAGAAGAAACCCTCAAGCAG
CAGAATGTTAGAGGAATGAAAAAATTGGATAATTATAAGAAAAAAGATCAGGAAACAAAA
AGATGGTTGAAAAATGCCTCTCCAGAAGATGTGGAATATTATAATTGCCAGCAAGAACTT
ACAGATGATCTACATAAACAGTATCAAATAGTGGGACGTATAATTGCTCATTCCAATCAA
AAGTCAGCAGCTGGTTATCCTGATTATTACTGCAAATGGCAGGGCCTTCCATACTCAGAG
TGCAGCTGGGAAGATGGAGCTCTCATTTCCAAAAAGTTTCAAGCATGCATTGATGAGTAT
TTTAGCAGGAACCAATCAAAAACCACTCCTTTTAAAGATTGCAAAGTATTAAAACAAAGG
CCAAGGTTTGTAGCCCTGAAGAAGCAGCCATCCTATATTGGAGGACATGAGGGCTTAGAA
TTAAGAGATTATCAACTGAATGGTTTAAATTGGCTTGCTCATTCTTGGTGCAAAGGAAAT
AGTTGCATACTCGCTGATGAAATGGGCCTTGGAAAAACAATACAGACGATCTCATTTCTG
AATTATTTGTTTCATGAACATCAATTATATGGACCTTTTTTATTGGTAGTACCGCTCTCC
ACTCTTACTTCCTGGCAAAGGGAAATTCAGACTTGGGCTTCTCAAATGAATGCTGTGGTT
TATTTAGGTGACATTAACAGCAGAAACATGATAAGAACTCATGAATGGACGCATCATCAG
ACCAAACGGTTAAAATTTAATATATTGTTAACAACTTATGAAATTTTATTAAAAGATAAG
GCATTCCTTGGAGGTCTAAATTGGGCATTTATAGGTGTTGATGAAGCACACCGATTAAAG
AATGATGACTCCCTTCTGTATAAAACTTTAATAGATTTTAAATCCAATCATCGTCTCCTT
ATCACTGGAACTCCTCTACAGAATTCCCTCAAAGAGCTCTGGTCTTTGCTACATTTCATT
ATGCCAGAAAAGTTTTCTTCCTGGGAAGATTTTGAAGAAGAACATGGCAAAGGGAGAGAA
TATGGTTATGCAAGCCTTCACAAGGAGCTTGAGCCATTTCTGTTACGCCGAGTTAAGAAA
GATGTGGAAAAATCTCTTCCTGCCAAGGTTGAGCAGATTTTAAGAATGGAAATGAGTGCT
TTACAGAAACAATATTACAAATGGATTTTAACTAGGAATTACAAAGCCCTCAGCAAAGGT
TCCAAGGGCAGTACCTCAGGCTTTTTGAACATTATGATGGAGCTAAAGAAATGTTGTAAC
CATTGCTACCTCATTAAACCACCAGATAATAATGAATTCTATAATAAACAGGAGGCCTTA
CAACACTTAATTCGTAGTAGCGGAAAATTGATTCTTCTTGACAAGCTATTAATTCGCCTA
AGAGAACGAGGCAATCGAGTTCTTATTTTTTCACAAATGGTGCGGATGTTAGATATACTT
GCAGAATATTTGAAATATCGTCAATTCCCCTTTCAAAGATTAGATGGATCAATAAAAGGA
GAACTGAGGAAACAAGCTCTAGATCATTTTAATGCTGAGGGATCAGAGGATTTTTGCTTT
TTGCTGTCCACAAGAGCTGGAGGTCTAGGGATTAATTTAGCCTCTGCTGACACTGTTGTT
ATATTTGATTCCGATTGGAATCCACAGAATGATCTTCAGGCACAGGCTAGAGCCCATCGA
ATTGGCCAAAAGAAACAGGTGAATATTTATCGTCTAGTTACAAAGGGATCAGTTGAAGAA
GATATTCTTGAAAGGGCGAAAAAGAAGATGGTTTTAGATCATCTTGTAATTCAAAGAATG
GACACAACTGGGAAGACAGTACTACATACAGGTTCTGCCCCATCAAGTTCTACTCCTTTC
AATAAAGAAGAGTTATCAGCCATTTTAAAGTTTGGTGCTGAAGAACTTTTTAAGGAACCT
GAAGGAGAAGAACAAGAGCCCCAGGAAATGGATATAGATGAAATCTTGAAGAGAGCTGAA
ACTCATGAAAATGAACCAGGTCCTTTAACTGTAGGAGATGAATTGCTTTCCCAGTTCAAG
GTTGCCAACTTCTCAAATATGGATGAGGATGACATTGAGTTGGAACCTGAAAGAAATTCA
AAGAATTGGGAGGAAATTATTCCAGAAGATCAAAGAAGACGATTAGAAGAAGAAGAAAGA
CAAAAGGAACTTGAAGAAATTTATATGCTCCCAAGAATGAGAAATTGTGCAAAACAGATT
AGTTTCAATGGAAGTGAAGGGAGGCGCAGTAGAAGTAGGAGATACTCTGGATCTGATAGT
GATTCCATCTCAGAAGGGAAAAGGCCAAAGAAACGTGGAAGACCACGGACTATTCCTCGG
GAGAATATTAAAGGATTTAGTGATGCAGAAATTAGGCGGTTTATCAAGAGCTATAAGAAA
TTTGGTGGTCCTCTGGAAAGATTAGATGCAATTGCTCGAGATGCTGAGTTAGTTGATAAG
TCAGAAACAGACCTTAGACGACTGGGAGAATTGGTACATAATGGTTGCATTAAAGCATTA
AAGGATAGTTCTTCAGGAACAGAACGAACAGGTGGTAGACTCGGAAAAGTGAAGGGTCCA
ACATTCCGAATATCAGGAGTACAGGTGAATGCCAAACTAGTCATCTCCCATGAAGAAGAA
TTAATACCTTTGCACAAATCCATTCCTTCTGATCCAGAAGAAAGAAAGCAGTATACTATC
CCATGCCACACAAAGGCAGCTCATTTTGATATAGACTGGGGCAAAGAAGATGATTCCAAT
TTGTTAATTGGCATCTATGAATATGGATATGGAAGCTGGGAAATGATTAAAATGGATCCT
GACCTCAGTCTAACACACAAGATTCTTCCAGATGATCCCGATAAAAAACCACAAGCAAAA
CAGTTGCAGACCCGTGCAGACTACCTCATCAAATTACTTAGTAGAGATCTTGCAAAAAAA
GAAGCTCTTTCTGGTGCGGGAAGTTCAAAGAGGAGAAAAGCAAGAGCTAAGAAGAATAAA
GCAATGAAGTCTATAAAAGTGAAAGAGGAAATAAAGAGTGATTCTTCTCCTCTGCCTTCA
GAGAAGTCTGATGAAGATGATGATAAATTGAGTGAATCCAAGTCTGATGGTAGGGAAAGA
TCCAAGAAATCTTCAGTGTCAGATGCTCCAGTTCATATCACGGCAAGTGGTGAACCAGTT
CCCATTTCTGAAGAATCTGAAGAGCTGGATCAGAAGACATTCAGCATTTGTAAAGAAAGA
ATGAGGCCTGTTAAAGCAGCTTTGAAACAACTTGATAGGCCTGAGAAAGGCCTTTCAGAA
AGAGAACAACTAGAACATACTAGACAATGTTTAATAAAAATTGGAGACCATATCACAGAA
TGTCTAAAAGAGTATACAAATCCTGAACAAATTAAGCAATGGAGAAAAAACCTGTGGATT
TTTGTATCTAAGTTTACTGAATTTGATGCAAGAAAATTACATAAATTATATAAGCATGCT
ATTAAAAAACGGCAGGAGTCTCAGCAAAACAGTGATCAAAACAGCAACTTGAATCCTCAC
GTGATTAGAAATCCAGATGTGGAAAGATTAAAAGAGAATACAAATCACGATGATAGCAGC
AGGGACAGTTATTCCTCTGATAGACACTTAACTCAGTACCATGATCATCATAAAGACCGA
CATCAGGGAGATTCTTACAAAAAAAGTGATTCCAGGAAAAGACCCTATTCTTCTTTTAGT
AATGGTAAAGACCATCGTGATTGGGATCACTACAAGCAAGACAGCAGATATTACAGTGAC
AGAGAGAAACACAGAAAACTGGATGATCACAGGAGTAGAGATCACAGGTCAAATTTGGAA
GGAAGTTTAAAAGATAGATCTCATTCTGATCATCGTTCTCACTCAGATCATCGGTTACAT
TCAGACCACCGGTCAAGTTCTGAATATACGCACCATAAATCTTCCAGGGATTATAGGTAT
CACTCAGACTGGCAAATGGACCACAGAGCTTCCAGCAGTGGCCCTAGGTCACCACTAGAT
CAGAGATCTTATGGCTCCAGATCTCCATTTGAACATTCAGTTGAACACAAAAGTACACCG
GAGCATACCTGGAGTAGTCGGAAAACATAA

# Drug_Target_1_General_Function:
Transcription

# Drug_Target_1_General_References:
12522270	Salomon AR, Ficarro SB, Brill LM, Brinker A, Phung QT, Ericson C, Sauer K, Brock A, Horn DM, Schultz PG, Peters EC: Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry. Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):443-8. Epub 2003 Jan 9.
9326634	Woodage T, Basrai MA, Baxevanis AD, Hieter P, Collins FS: Characterization of the CHD family of proteins. Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11472-7.

# Drug_Target_1_HGNC_ID:
HGNC:1915

# Drug_Target_1_HPRD_ID:
03668

# Drug_Target_1_ID:
588

# Drug_Target_1_Locus:
5q15-q21

# Drug_Target_1_Molecular_Weight:
196520

# Drug_Target_1_Name:
Chromodomain-helicase-DNA-binding protein 1

# Drug_Target_1_Number_of_Residues:
1709

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00176	SNF2_N
PF00271	Helicase_C
PF00385	Chromo

# Drug_Target_1_Protein_Sequence:
>Chromodomain-helicase-DNA-binding protein 1
MNGHSDEESVRNSSGESSQSDDDSGSASGSGSGSSSGSSSDGSSSQSGSSDSDSGSESGS
QSESESDTSRENKVQAKPPKVDGAEFWKSSPSILAVQRSAILKKQQQQQQQQQHQASSNS
GSEEDSSSSEDSDDSSSEVKRKKHKDEDWQMSGSGSPSQSGSDSESEEEREKSSCDETES
DYEPKNKVKSRKPQNRSKSKNGKKILGQKKRQIDSSEEDDDEEDYDNDKRSSRRQATVNV
SYKEDEEMKTDSDDLLEVCGEDVPQPEEEEFETIERFMDCRIGRKGATGATTTIYAVEAD
GDPNAGFEKNKEPGEIQYLIKWKGWSHIHNTWETEETLKQQNVRGMKKLDNYKKKDQETK
RWLKNASPEDVEYYNCQQELTDDLHKQYQIVGRIIAHSNQKSAAGYPDYYCKWQGLPYSE
CSWEDGALISKKFQACIDEYFSRNQSKTTPFKDCKVLKQRPRFVALKKQPSYIGGHEGLE
LRDYQLNGLNWLAHSWCKGNSCILADEMGLGKTIQTISFLNYLFHEHQLYGPFLLVVPLS
TLTSWQREIQTWASQMNAVVYLGDINSRNMIRTHEWTHHQTKRLKFNILLTTYEILLKDK
AFLGGLNWAFIGVDEAHRLKNDDSLLYKTLIDFKSNHRLLITGTPLQNSLKELWSLLHFI
MPEKFSSWEDFEEEHGKGREYGYASLHKELEPFLLRRVKKDVEKSLPAKVEQILRMEMSA
LQKQYYKWILTRNYKALSKGSKGSTSGFLNIMMELKKCCNHCYLIKPPDNNEFYNKQEAL
QHLIRSSGKLILLDKLLIRLRERGNRVLIFSQMVRMLDILAEYLKYRQFPFQRLDGSIKG
ELRKQALDHFNAEGSEDFCFLLSTRAGGLGINLASADTVVIFDSDWNPQNDLQAQARAHR
IGQKKQVNIYRLVTKGSVEEDILERAKKKMVLDHLVIQRMDTTGKTVLHTGSAPSSSTPF
NKEELSAILKFGAEELFKEPEGEEQEPQEMDIDEILKRAETHENEPGPLTVGDELLSQFK
VANFSNMDEDDIELEPERNSKNWEEIIPEDQRRRLEEEERQKELEEIYMLPRMRNCAKQI
SFNGSEGRRSRSRRYSGSDSDSISEGKRPKKRGRPRTIPRENIKGFSDAEIRRFIKSYKK
FGGPLERLDAIARDAELVDKSETDLRRLGELVHNGCIKALKDSSSGTERTGGRLGKVKGP
TFRISGVQVNAKLVISHEEELIPLHKSIPSDPEERKQYTIPCHTKAAHFDIDWGKEDDSN
LLIGIYEYGYGSWEMIKMDPDLSLTHKILPDDPDKKPQAKQLQTRADYLIKLLSRDLAKK
EALSGAGSSKRRKARAKKNKAMKSIKVKEEIKSDSSPLPSEKSDEDDDKLSESKSDGRER
SKKSSVSDAPVHITASGEPVPISEESEELDQKTFSICKERMRPVKAALKQLDRPEKGLSE
REQLEHTRQCLIKIGDHITECLKEYTNPEQIKQWRKNLWIFVSKFTEFDARKLHKLYKHA
IKKRQESQQNSDQNSNLNPHVIRNPDVERLKENTNHDDSSRDSYSSDRHLTQYHDHHKDR
HQGDSYKKSDSRKRPYSSFSNGKDHRDWDHYKQDSRYYSDREKHRKLDDHRSRDHRSNLE
GSLKDRSHSDHRSHSDHRLHSDHRSSSEYTHHKSSRDYRYHSDWQMDHRASSSGPRSPLD
QRSYGSRSPFEHSVEHKSTPEHTWSSRKT

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Sequence-selective DNA-binding protein. Could play an important role in gene regulation

# Drug_Target_1_SwissProt_ID:
O14646

# Drug_Target_1_SwissProt_Name:
CHD1_HUMAN

# Drug_Target_1_Synonyms:
ATP- dependent helicase CHD1
CHD-1
EC 3.6.1.-

# Drug_Target_1_Theoretical_pI:
7.17

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm. Nucleus
nucleoplasm. Generally located in the nucleoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
14728934	Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegele P, Eber M, Ghnassia JP: Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004 Jan;40(2):205-11.
16234514	Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdottir K, Olsen KE, Mouridsen H, Ejlertsen B: retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005 Oct 20;23(30):7483-90.
17639997	Liang CH, Shiu LY, Chang LC, Sheu HM, Kuo KW: Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells. Mol Nutr Food Res. 2007 Aug;51(8):999-1005.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
TOP2A

# Drug_Target_2_GenBank_ID_Gene:
J04088

# Drug_Target_2_GenBank_ID_Protein:
292830

# Drug_Target_2_GeneCard_ID:
TOP2A

# Drug_Target_2_Gene_Name:
TOP2A

# Drug_Target_2_Gene_Sequence:
>4596 bp
ATGGAAGTGTCACCATTGCAGCCTGTAAATGAAAATATGCAAGTCAACAAAATAAAGAAA
AATGAAGATGCTAAGAAAAGACTGTCTGTTGAAAGAATCTATCAAAAGAAAACACAATTG
GAACATATTTTGCTCCGCCCAGACACCTACATTGGTTCTGTGGAATTAGTGACCCAGCAA
ATGTGGGTTTACGATGAAGATGTTGGCATTAACTATAGGGAAGTCACTTTTGTTCCTGGT
TTGTACAAAATCTTTGATGAGATTCTAGTTAATGCTGCGGACAACAAACAAAGGGACCCA
AAAATGTCTTGTATTAGAGTCACAATTGATCCGGAAAACAATTTAATTAGTATATGGAAT
AATGGAAAAGGTATTCCTGTTGTTGAACACAAAGTTGAAAAGATGTATGTCCCAGCTCTC
ATATTTGGACAGCTCCTAACTTCTAGTAACTATGATGATGATGAAAAGAAAGTGACAGGT
GGTCGAAATGGCTATGGAGCCAAATTGTGTAACATATTCAGTACCAAATTTACTGTGGAA
ACAGCCAGTAGAGAATACAAGAAAATGTTCAAACAGACATGGATGGATAATATGGGAAGA
GCTGGTGAGATGGAACTCAAGCCCTTCAATGGAGAAGATTATACATGTATCACCTTTCAG
CCTGATTTGTCTAAGTTTAAAATGCAAAGCCTGGACAAAGATATTGTTGCACTAATGGTC
AGAAGAGCATATGATATTGCTGGATCCACCAAAGATGTCAAAGTCTTTCTTAATGGAAAT
AAACTGCCAGTAAAAGGATTTCGTAGTTATGTGGACATGTATTTGAAGGACAAGTTGGAT
GAAACTGGTAACTCCTTGAAAGTAATACATGAACAAGTAAACCACAGGTGGGAAGTGTGT
TTAACTATGAGTGAAAAAGGCTTTCAGCAAATTAGCTTTGTCAACAGCATTGCTACATCC
AAGGGTGGCAGACATGTTGATTATGTAGCTGATCAGATTGTGACTAAACTTGTTGATGTT
GTGAAGAAGAAGAACAAGGGTGGTGTTGCAGTAAAAGCACATCAGGTGAAAAATCACATG
TGGATTTTTGTAAATGCCTTAATTGAAAACCCAACCTTTGACTCTCAGACAAAAGAAAAC
ATGACTTTACAACCCAAGAGCTTTGGATCAACATGCCAATTGAGTGAAAAATTTATCAAA
GCTGCCATTGGCTGTGGTATTGTAGAAAGCATACTAAACTGGGTGAAGTTTAAGGCCCAA
GTCCAGTTAAACAAGAAGTGTTCAGCTGTAAAACATAATAGAATCAAGGGAATTCCCAAA
CTCGATGATGCCAATGATGCAGGGGGCCGAAACTCCACTGAGTGTACGCTTATCCTGACT
GAGGGAGATTCAGCCAAAACTTTGGCTGTTTCAGGCCTTGGTGTGGTTGGGAGAGACAAA
TATGGGGTTTTCCCTCTTAGAGGAAAAATACTCAATGTTCGAGAAGCTTCTCATAAGCAG
ATCATGGAAAATGCTGAGATTAACAATATCATCAAGATTGTGGGTCTTCAGTACAAGAAA
AACTATGAAGATGAAGATTCATTGAAGACGCTTCGTTATGGGAAGATAATGATTATGACA
GATCAGGACCAAGATGGTTCCCACATCAAAGGCTTGCTGATTAATTTTATCCATCACAAC
TGGCCCTCTCTTCTGCGACATCGTTTTCTGGAGGAATTTATCACTCCCATTGTAAAGGTA
TCTAAAAACAAGCAAGAAATGGCATTTTACAGCCTTCCTGAATTTGAAGAGTGGAAGAGT
TCTACTCCAAATCATAAAAAATGGAAAGTCAAATATTACAAAGGTTTGGGCACCAGCACA
TCAAAGGAAGCTAAAGAATACTTTGCAGATATGAAAAGACATCGTATCCAGTTCAAATAT
TCTGGTCCTGAAGATGATGCTGCTATCAGCCTGGCCTTTAGCAAAAAACAGATAGATGAT
CGAAAGGAATGGTTAACTAATTTCATGGAGGATAGAAGACAACGAAAGTTACTTGGGCTT
CCTGAGGATTACTTGTATGGACAAACTACCACATATCTGACATATAATGACTTCATCAAC
AAGGAACTTATCTTGTTCTCAAATTCTGATAACGAGAGATCTATCCCTTCTATGGTGGAT
GGTTTGAAACCAGGTCAGAGAAAGGTTTTGTTTACTTGCTTCAAACGGAATGACAAGCGA
GAAGTAAAGGTTGCCCAATTAGCTGGATCAGTGGCTGAAATGTCTTCTTATCATCATGGT
GAGATGTCACTAATGATGACCATTATCAATTTGGCTCAGAATTTTGTGGGTAGCAATAAT
CTAAACCTCTTGCAGCCCATTGGTCAGTTTGGTACCAGGCTACATGGTGGCAAGGATTCT
GCTAGTCCACGATACATCTTTACAATGCTCAGCTCTTTGGCTCGATTGTTATTTCCACCA
AAAGATGATCACACGTTGAAGTTTTTATATGATGACAACCAGCGTGTTGAGCCTGAATGG
TACATTCCTATTATTCCCATGGTGCTGATAAATGGTGCTGAAGGAATCGGTACTGGGTGG
TCCTGCAAAATCCCCAACTTTGATGTGCGTGAAATTGTAAATAACATCAGGCGTTTGATG
GATGGAGAAGAACCTTTGCCAATGCTTCCAAGTTACAAGAACTTCAAGGGTACTATTGAA
GAACTGGCTCCAAATCAATATGTGATTAGTGGTGAAGTAGCTATTCTTAATTCTACAACC
ATTGAAATCTCAGAGCTTCCCGTCAGAACATGGACCCAGACATACAAAGAACAAGTTCTA
GAACCCATGTTGAATGGCACCGAGAAGACACCTCCTCTCATAACAGACTATAGGGAATAC
CATACAGATACCACTGTGAAATTTGTTGTGAAGATGACTGAAGAAAAACTGGCAGAGGCA
GAGAGAGTTGGACTACACAAAGTCTTCAAACTCCAAACTAGTCTCACATGCAACTCTATG
GTGCTTTTTGACCACGTAGGCTGTTTAAAGAAATATGACACGGTGTTGGATATTCTAAGA
GACTTTTTTGAACTCAGACTTAAATATTATGGATTAAGAAAAGAATGGCTCCTAGGAATG
CTTGGTGCTGAATCTGCTAAACTGAATAATCAGGCTCGCTTTATCTTAGAGAAAATAGAT
GGCAAAATAATCATTGAAAATAAGCCTAAGAAAGAATTAATTAAAGTTCTGATTCAGAGG
GGATATGATTCGGATCCTGTGAAGGCCTGGAAAGAAGCCCAGCAAAAGGTTCCAGATGAA
GAAGAAAATGAAGAGAGTGACAACGAAAAGGAAACTGAAAAGAGTGACTCCGTAACAGAT
TCTGGACCAACCTTCAACTATCTTCTTGATATGCCCCTTTGGTATTTAACCAAGGAAAAG
AAAGATGAACTCTGCAGGCTAAGAAATGAAAAAGAACAAGAGCTGGACACATTAAAAAGA
AAGAGTCCATCAGATTTGTGGAAAGAAGACTTGGCTACATTTATTGAAGAATTGGAGGCT
GTTGAAGCCAAGGAAAAACAAGATGAACAAGTCGGACTTCCTGGGAAAGGGGGGAAGGCC
AAGGGGAAAAAAACACAAATGGCTGAAGTTTTGCCTTCTCCGCGTGGTCAAAGAGTCATT
CCACGAATAACCATAGAAATGAAAGCAGAGGCAGAAAAGAAAAATAAAAAGAAAATTAAG
AATGAAAATACTGAAGGAAGCCCTCAAGAAGATGGTGTGGAACTAGAAGGCCTAAAACAA
AGATTAGAAAAGAAACAGAAAAGAGAACCAGGTACAAAGACAAAGAAACAAACTACATTG
GCATTTAAGCCAATCAAAAAAGGAAAGAAGAGAAATCCCTGGCCTGATTCAGAATCAGAT
AGGAGCAGTGACGAAAGTAATTTTGATGTCCCTCCACGAGAAACAGAGCCACGGAGAGCA
GCAACAAAAACAAAATTCACAATGGATTTGGATTCAGATGAAGATTTCTCAGATTTTGAT
GAAAAAACTGATGATGAAGATTTTGTCCCATCAGATGCTAGTCCACCTAAGACCAAAACT
TCCCCAAAACTTAGTAACAAAGAACTGAAACCACAGAAAAGTGTCGTGTCAGACCTTGAA
GCTGATGATGTTAAGGGCAGTGTACCACTGTCTTCAAGCCCTCCTGCTACACATTTCCCA
GATGAAACTGAAATTACAAACCCAGTTCCTAAAAAGAATGTGACAGTGAAGAAGACAGCA
GCAAAAAGTCAGTCTTCCACCTCCACTACCGGTGCCAAAAAAAGGGCTGCCCCAAAAGGA
ACTAAAAGGGATCCAGCTTTGAATTCTGGTGTCTCTCAAAAGCCTGATCCTGCCAAAACC
AAGAATCGCCGCAAAAGGAAGCCATCCACTTCTGATGATTCTGACTCTAATTTTGAGAAA
ATTGTTTCGAAAGCAGTCACAAGCAAGAAATCCAAGGGGGAGAGTGATGACTTCCATATG
GACTTTGACTCAGCTGTGGCTCCTCGGGCAAAATCTGTACGGGCAAAGAAACCTATAAAG
TACCTGGAAGAGTCAGATGAAGATGATCTGTTTTAA

# Drug_Target_2_General_Function:
Replication, recombination and repair

# Drug_Target_2_General_References:
10095062	Sng JH, Heaton VJ, Bell M, Maini P, Austin CA, Fisher LM: Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication. Biochim Biophys Acta. 1999 Mar 19;1444(3):395-406.
10942766	Escargueil AE, Plisov SY, Filhol O, Cochet C, Larsen AK: Mitotic phosphorylation of DNA topoisomerase II alpha by protein kinase CK2 creates the MPM-2 phosphoepitope on Ser-1469. J Biol Chem. 2000 Nov 3;275(44):34710-8.
12821127	Mirski SE, Bielawski JC, Cole SP: Identification of functional nuclear export sequences in human topoisomerase IIalpha and beta. Biochem Biophys Res Commun. 2003 Jul 11;306(4):905-11.
1651812	Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD, Zwelling LA: Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res. 1991 Sep 1;51(17):4729-31.
1652758	Bugg BY, Danks MK, Beck WT, Suttle DP: Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7654-8.
2845399	Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Wang JC: Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7177-81.
8393377	Wasserman RA, Austin CA, Fisher LM, Wang JC: Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast. Cancer Res. 1993 Aug 1;53(15):3591-6.
9795238	Lang AJ, Mirski SE, Cummings HJ, Yu Q, Gerlach JH, Cole SP: Structural organization of the human TOP2A and TOP2B genes. Gene. 1998 Oct 23;221(2):255-66.

# Drug_Target_2_HGNC_ID:
HGNC:11989

# Drug_Target_2_HPRD_ID:
00536

# Drug_Target_2_ID:
817

# Drug_Target_2_Locus:
17q21-q22

# Drug_Target_2_Molecular_Weight:
174387

# Drug_Target_2_Name:
DNA topoisomerase 2-alpha

# Drug_Target_2_Number_of_Residues:
1531

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Etoposide Pathway	SMP00442
Teniposide Pathway	SMP00443

# Drug_Target_2_Pfam_Domain_Function:
PF00204	DNA_gyraseB
PF00521	DNA_topoisoIV
PF02518	HATPase_c
PF08070	DTHCT

# Drug_Target_2_Protein_Sequence:
>DNA topoisomerase 2-alpha
MEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQ
MWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWN
NGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVE
TASREYKKMFKQTWMDNMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMV
RRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVC
LTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHM
WIFVNALIENPTFDSQTKENMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQ
VQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDK
YGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMT
DQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKS
STPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDD
RKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVD
GLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNN
LNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEW
YIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIE
ELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREY
HTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILR
DFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQR
GYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEK
KDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKA
KGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQ
RLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRA
ATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLE
ADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKG
TKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHM
DFDSAVAPRAKSVRAKKPIKYLEESDEDDLF

# Drug_Target_2_Reaction:
ATP-dependent breakage, passage and rejoining of double-stranded DNA INHIBITOR Coumermycin A1; GRI22222X; Nalidixic acid; Novobiocin; Ciprofloxacin

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks

# Drug_Target_2_SwissProt_ID:
P11388

# Drug_Target_2_SwissProt_Name:
TOP2A_HUMAN

# Drug_Target_2_Synonyms:
DNA topoisomerase II, alpha isozyme
EC 5.99.1.3

# Drug_Target_2_Theoretical_pI:
9.17

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Nucleus and mitochondria

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
10489446	Podell ER, Harrington DJ, Taatjes DJ, Koch TH: Crystal structure of epidoxorubicin-formaldehyde virtual crosslink of DNA and evidence for its formation in human breast-cancer cells. Acta Crystallogr D Biol Crystallogr. 1999 Sep;55(Pt 9):1516-23.
2216725	Williams LD, Frederick CA, Ughetto G, Rich A: Ternary interactions of spermine with DNA: 4'-epiadriamycin and other DNA: anthracycline complexes. Nucleic Acids Res. 1990 Sep 25;18(18):5533-41.
6342772	Ganzina F: 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev. 1983 Mar;10(1):1-22.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
Not Available

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
Not Available

# Drug_Target_3_Gene_Sequence:
>Example: Dickerson dodecamer
CGCGAATTCGCG

# Drug_Target_3_General_Function:
Biological information storage and information transfer

# Drug_Target_3_General_References:
1234	Nadeau D, Marchand C: Change in the kinetics of sulphacetamide tissue distribution in Walker tumor-bearing rats. Drug Metab Dispos. 1975 Nov-Dec;3(6):565-76.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
874

# Drug_Target_3_Locus:
All loci

# Drug_Target_3_Molecular_Weight:
7656 (double strand)

# Drug_Target_3_Name:
DNA

# Drug_Target_3_Number_of_Residues:
0

# Drug_Target_3_PDB_ID:
1BNA

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
Not Available

# Drug_Target_3_Protein_Sequence:
Not Available

# Drug_Target_3_Reaction:
DNA + DNA polymerase + nNTP = 2 DNA + nNDP; DNA + RNA polymerase + NTP = mRNA + nNDP

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

# Drug_Target_3_SwissProt_ID:
Not Available

# Drug_Target_3_SwissProt_Name:
Not Available

# Drug_Target_3_Synonyms:
Deoxyribonucleic acid

# Drug_Target_3_Theoretical_pI:
Not Available

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00445
